Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for plerixafor (compound)

Name: JM 3100
PubChem Compound ID: 65014
Molecular formula: C28H62Cl8N8
Molecular weight: 794.467 g/mol
1,1'-(1,4-Phenylenebis(methylene))bis-1,4,8,11-tetraazacyclotetradecane octahydrochloride; Bicyclam; 1,1'-(1,4-Phenylenebis-(methylene))-bis-1,4,8,11-tetraazacyclotetradecane octahydrochloride dihydrate; AMD-3100; Amd 3100; JM 3100; SDZ-SID-791; 155148-31-5; JM-3100; 1,4,8,11-Tetraazacyclotetradecane, 1,1'-(1,4-phenylenebis(methylene))bis-, octahydrochloride.
show more »
Name: JM 3100
Name (isomeric): DB06809
Drug Type: small molecule
Brand: Mozobil
CAS number: 110078-46-1
Indication: Used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM).
Pharmacology: Plerixafor increases circulating CD34+ cells in the peripheral blood, with a peak effect about 6-9 hours.
Mechanism of Action: Plerixafor inhibits the CXCR4 chemokine receptor and blocks binding to the marrow compartment of its cognate ligand, SDF-1alpha, which play a role in the trafficking and homing of human hematopoietic stem cells.
Absorption: Plerixafor is rapidly absorbed after subcutaneous injection (Tmax = 30-60 min).
Protein binding: Plerixafor is bound to human plasma proteins up to 58%.
Route of elimination: Approximately 70% of the parent drug is excreted in urine during first 24 h.
Half Life: Terminal half-life ranges from 3 to 5 hours.